Nombulelo Magula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nombulelo Magula has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Somasundram Pillay
University of KwaZulu-Natal
4 shared publications - Deepak Singh
Durban University of Technology
2 shared publications - Nceba Gqaleni
Sub-Discipline of Traditional Medicine, School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
2 shared publications - Alex Sigal
Africa Health Research Institute and University of KwaZulu-Natal, Durban, South Africa
1 shared publication - Andrew J. McKune
University of Canberra
1 shared publication - Anne von Gottberg
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service , Johannesburg
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 1
Corrigendum: Unlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 1
Open AccessCorrigendum: Unlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.
- Open Access
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 8
Unlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa
Background: Key populations experience disproportionate HIV burdens and structural barriers to care. Objective: To compare healthcare utilisation, HIV knowledge and barriers between key population groups (KPG) and non-key populations living with HIV in eThekwini, South Africa. Methods: We analysed the eThekwini Fast-Track Cities Quality of Care survey, a cross-sectional study across 30 high-HIV-burden facilities (April to July 2023). Adults living with HIV completed anonymous questionnaires; groups were compared using χ2 tests and multivariable logistic regression for partner notification. Results: Of 517 analysed participants, 128 (24.8%) were KPG. KPG participants were younger, more recently diagnosed (< 1 year: 9.4% vs 1.3%) and more often on antiretroviral therapy (ART) for 1–4 years (52.3% vs 33.4%), with similar daily adherence (~83%). KPG were more likely to access care via non-governmental organisations (NGOs; 23.4% vs 5.7%). Controls more often understood undetectable viral load (36.0% vs 21.9%) and that treatment benefits outweigh side effects (65.3% vs 42.9%). KPG more frequently reported undetectable viral load (55.5% vs 29.8%), more frequent screening for co-morbid conditions, and transport-cost barriers (15.6% vs 8.2%). In KPG, NGO care was associated with partner notification (adjusted odds ratio 18.06; 95% confidence interval 4.77–68.41). Conclusion: There are marked differences between KPG and adults with HIV in healthcare utilisation, HIV knowledge and structural barriers.
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 8
Open AccessUnlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa
Background: Key populations experience disproportionate HIV burdens and structural barriers to care. Objective: To compare healthcare utilisation, HIV knowledge and barriers between key population groups (KPG) and non-key populations living with HIV in eThekwini, South Africa. Methods: We analysed the eThekwini Fast-Track Cities Quality of Care survey, a cross-sectional study across 30 high-HIV-burden facilities (April to July 2023). Adults living with HIV completed anonymous questionnaires; groups were compared using χ2 tests and multivariable logistic regression for partner notification. Results: Of 517 analysed participants, 128 (24.8%) were KPG. KPG participants were younger, more recently diagnosed (< 1 year: 9.4% vs 1.3%) and more often on antiretroviral therapy (ART) for 1–4 years (52.3% vs 33.4%), with similar daily adherence (~83%). KPG were more likely to access care via non-governmental organisations (NGOs; 23.4% vs 5.7%). Controls more often understood undetectable viral load (36.0% vs 21.9%) and that treatment benefits outweigh side effects (65.3% vs 42.9%). KPG more frequently reported undetectable viral load (55.5% vs 29.8%), more frequent screening for co-morbid conditions, and transport-cost barriers (15.6% vs 8.2%). In KPG, NGO care was associated with partner notification (adjusted odds ratio 18.06; 95% confidence interval 4.77–68.41). Conclusion: There are marked differences between KPG and adults with HIV in healthcare utilisation, HIV knowledge and structural barriers.
- Open Access
- 15 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation
SARS-CoV-2 clearance requires adaptive immunity but the contribution of neutralizing antibodies and T cells in different immune states is unclear. Here we ask which adaptive immune responses associate with clearance of long-term SARS-CoV-2 infection in HIV-mediated immunosuppression after suppressive antiretroviral therapy (ART) initiation. We assembled a cohort of SARS-CoV-2 infected people in South Africa (n = 994) including participants with advanced HIV disease characterized by immunosuppression due to T cell depletion. Fifty-four percent of participants with advanced HIV disease had prolonged SARS-CoV-2 infection (>1 month). In the five vaccinated participants with advanced HIV disease tested, SARS-CoV-2 clearance associates with emergence of neutralizing antibodies but not SARS-CoV-2 specific CD8 T cells, while CD4 T cell responses were not determined due to low cell numbers. Further, complete HIV suppression is not required for clearance, although it is necessary for an effective vaccine response. Persistent SARS-CoV-2 infection led to SARS-CoV-2 evolution, including virus with extensive neutralization escape in a Delta variant infected participant. The results provide evidence that neutralizing antibodies are required for SARS-CoV-2 clearance in HIV-mediated immunosuppression recovery, and that suppressive ART is necessary to curtail evolution of co-infecting pathogens to reduce individual health consequences as well as public health risk linked with generation of escape mutants.
- 15 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessClearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation
SARS-CoV-2 clearance requires adaptive immunity but the contribution of neutralizing antibodies and T cells in different immune states is unclear. Here we ask which adaptive immune responses associate with clearance of long-term SARS-CoV-2 infection in HIV-mediated immunosuppression after suppressive antiretroviral therapy (ART) initiation. We assembled a cohort of SARS-CoV-2 infected people in South Africa (n = 994) including participants with advanced HIV disease characterized by immunosuppression due to T cell depletion. Fifty-four percent of participants with advanced HIV disease had prolonged SARS-CoV-2 infection (>1 month). In the five vaccinated participants with advanced HIV disease tested, SARS-CoV-2 clearance associates with emergence of neutralizing antibodies but not SARS-CoV-2 specific CD8 T cells, while CD4 T cell responses were not determined due to low cell numbers. Further, complete HIV suppression is not required for clearance, although it is necessary for an effective vaccine response. Persistent SARS-CoV-2 infection led to SARS-CoV-2 evolution, including virus with extensive neutralization escape in a Delta variant infected participant. The results provide evidence that neutralizing antibodies are required for SARS-CoV-2 clearance in HIV-mediated immunosuppression recovery, and that suppressive ART is necessary to curtail evolution of co-infecting pathogens to reduce individual health consequences as well as public health risk linked with generation of escape mutants.
- Open Access
- 25 January 2024
- Published by AOSIS in South African Family Practice
- Vol. 66 (1) , 7-e7
Assessing index CD4 and associated outcomes at 1-year in a tertiary HIV clinic, KwaZulu-Natal
Background: Human immunodeficiency virus (HIV) management guidelines have evolved from initiating therapy at CD4 counts of ≤ 200 cells/m3 to implementing universal test and treat (UTT). This study aimed to assess whether in clinical practice, patients are presenting with higher baseline CD4 counts, describe the incidence of opportunistic infections and the proportion that achieved viral suppression. Methods: A retrospective cohort design with convenience sampling was conducted. Cohort 1 included patients initiated on antiretroviral therapy (ART) between 01 January 2014 and 31 December 2014, when criteria were set at CD4 count ≤ 350 cells/mm3. Cohort 2 included patients initiated on ART between 01 January 2019 and 31 December 2019, during the UTT era. Results: At ART initiation, the median CD4 cell was 170 cells/mm3 (interquartile range [IQR]: 85.5–287) in Cohort 1 cells/mm3 and 243 cells/mm3 (IQR: 120–411) in Cohort 2. Tuberculosis was the predominant OI in the group with CD4 cell count ≤ 200 cells/m3 in both Cohort 1 (26.8%) and Cohort 2 (27.9%), p = 0.039. At 1 year, virological suppression was achieved in only 77.7% and 84.7% of Cohorts 1 and 2 patients. Conclusion: A notable portion of patients at King Edward VIII Hospital’s HIV clinic commenced ART with CD4 counts significantly below the recommended guideline thresholds. Contribution: The research revealed a delay in initiating ART. A comprehensive reevaluation is essential to pinpoint the factors contributing to this delay and to devise customised interventions.
- 25 January 2024
- Published by AOSIS in South African Family Practice
- Vol. 66 (1) , 7-e7
Open AccessAssessing index CD4 and associated outcomes at 1-year in a tertiary HIV clinic, KwaZulu-Natal
Background: Human immunodeficiency virus (HIV) management guidelines have evolved from initiating therapy at CD4 counts of ≤ 200 cells/m3 to implementing universal test and treat (UTT). This study aimed to assess whether in clinical practice, patients are presenting with higher baseline CD4 counts, describe the incidence of opportunistic infections and the proportion that achieved viral suppression. Methods: A retrospective cohort design with convenience sampling was conducted. Cohort 1 included patients initiated on antiretroviral therapy (ART) between 01 January 2014 and 31 December 2014, when criteria were set at CD4 count ≤ 350 cells/mm3. Cohort 2 included patients initiated on ART between 01 January 2019 and 31 December 2019, during the UTT era. Results: At ART initiation, the median CD4 cell was 170 cells/mm3 (interquartile range [IQR]: 85.5–287) in Cohort 1 cells/mm3 and 243 cells/mm3 (IQR: 120–411) in Cohort 2. Tuberculosis was the predominant OI in the group with CD4 cell count ≤ 200 cells/m3 in both Cohort 1 (26.8%) and Cohort 2 (27.9%), p = 0.039. At 1 year, virological suppression was achieved in only 77.7% and 84.7% of Cohorts 1 and 2 patients. Conclusion: A notable portion of patients at King Edward VIII Hospital’s HIV clinic commenced ART with CD4 counts significantly below the recommended guideline thresholds. Contribution: The research revealed a delay in initiating ART. A comprehensive reevaluation is essential to pinpoint the factors contributing to this delay and to devise customised interventions.
- 1 September 2021
- Published by African Journal for Physical Activity and Health Sciences, Tshwane University of Technology in African Journal for Physical Activity and Health Sciences (AJPHES)
- Vol. 27 (3) , 288-303
Progressive resistance training irrespective of whey protein intake improves quality of life in HIV-infected individuals on antiretroviral therapy
The study aimed to determine whether a progressive resistance training (PRT) programme and whey protein intake could affect the quality of life (QOL) in HIV-infected individuals receiving antiretroviral therapy (ART). Sixty HIV-infected individuals were ...
- 1 September 2021
- Published by African Journal for Physical Activity and Health Sciences, Tshwane University of Technology in African Journal for Physical Activity and Health Sciences (AJPHES)
- Vol. 27 (3) , 288-303
Progressive resistance training irrespective of whey protein intake improves quality of life in HIV-infected individuals on antiretroviral therapy
The study aimed to determine whether a progressive resistance training (PRT) programme and whey protein intake could affect the quality of life (QOL) in HIV-infected individuals receiving antiretroviral therapy (ART). Sixty HIV-infected individuals were ...
- Open Access
- 7 April 2021
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 36 (1) , 7
Treatment outcomes of Gene Xpert positive tuberculosis patients in KwaMashu Community Health Centre, KwaZulu-Natal, South Africa: A retrospective review
Background: We sought to investigate the relationship between tuberculosis (TB) treatment outcomes and its predictors in the KwaMashu region in KwaZulu-Natal (KZN). This area is currently a hotbed for TB and human immunodeficiency virus (HIV) co-infection. Method: A retrospective study design was adopted to characterise adult patients diagnosed with Gene Expert (GXP) positive pulmonary TB from 01 January 2016 to 31 December 2017. Tuberculosis treatment outcomes were assessed after two months and five months according to the standard World Health Organization (WHO) criteria. Multiple logistic regression analysis was used to calculate the odds ratio (OR) of the possible determinants associated with unsuccessful treatment outcomes. Results: Amongst the 596 patients diagnosed, 57.4% (95% confidence interval [CI]: 53.3–61.4; 342 of 596) had successful treatment outcomes. Of these reported cases, 88.89% (85.1–92.0; 304 of 342) were cured. For the unsuccessful treatment outcomes, 52.4% (46.0–58.6; 133 of 254) patients were lost to follow-up, 20.9% (16.0–26.4; 53 of 254) failed treatment, 1.2% (0.2–3.4; 3 of 254) died and 25.6% (20.3–31.4; 65 of 254) of the patients could not be accounted for. Patients with unknown HIV status were more likely to have unsuccessful treatment outcomes (adjusted OR [aOR] = 4.94 [1.83–13.36]). Patients who had sputum conversion at 2 months (aOR = 1.94 [1.27–2.96]) were significantly more likely to exhibit unsuccessful treatment outcomes. Conclusion: Treatment success rate was 57.4% which was below the target set by the WHO. This underscores the urgent need to strengthen treatment adherence strategies to improve outcomes, especially in high HIV burden settings.
- 7 April 2021
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 36 (1) , 7
Open AccessTreatment outcomes of Gene Xpert positive tuberculosis patients in KwaMashu Community Health Centre, KwaZulu-Natal, South Africa: A retrospective review
Background: We sought to investigate the relationship between tuberculosis (TB) treatment outcomes and its predictors in the KwaMashu region in KwaZulu-Natal (KZN). This area is currently a hotbed for TB and human immunodeficiency virus (HIV) co-infection. Method: A retrospective study design was adopted to characterise adult patients diagnosed with Gene Expert (GXP) positive pulmonary TB from 01 January 2016 to 31 December 2017. Tuberculosis treatment outcomes were assessed after two months and five months according to the standard World Health Organization (WHO) criteria. Multiple logistic regression analysis was used to calculate the odds ratio (OR) of the possible determinants associated with unsuccessful treatment outcomes. Results: Amongst the 596 patients diagnosed, 57.4% (95% confidence interval [CI]: 53.3–61.4; 342 of 596) had successful treatment outcomes. Of these reported cases, 88.89% (85.1–92.0; 304 of 342) were cured. For the unsuccessful treatment outcomes, 52.4% (46.0–58.6; 133 of 254) patients were lost to follow-up, 20.9% (16.0–26.4; 53 of 254) failed treatment, 1.2% (0.2–3.4; 3 of 254) died and 25.6% (20.3–31.4; 65 of 254) of the patients could not be accounted for. Patients with unknown HIV status were more likely to have unsuccessful treatment outcomes (adjusted OR [aOR] = 4.94 [1.83–13.36]). Patients who had sputum conversion at 2 months (aOR = 1.94 [1.27–2.96]) were significantly more likely to exhibit unsuccessful treatment outcomes. Conclusion: Treatment success rate was 57.4% which was below the target set by the WHO. This underscores the urgent need to strengthen treatment adherence strategies to improve outcomes, especially in high HIV burden settings.
- Open Access
- 28 January 2021
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 22 (1) , 4
A trio of infectious diseases and pulmonary embolism: A developing world’s reality
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.
- 28 January 2021
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 22 (1) , 4
Open AccessA trio of infectious diseases and pulmonary embolism: A developing world’s reality
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.
- Open Access
- 19 January 2018
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 19 (1) , 11
Risk factors and co-morbidities associated with changes in renal function among antiretroviral treatment-naïve adults in South Africa: A chart review
Introduction: Our systematic scoping review has demonstrated a research gap in antiretroviral treatment (ART) nephrotoxicity as well as in the long-term outcomes of renal function for patients on ART in South Africa. Bearing in mind the high prevalence of human immunodeficiency virus (HIV) in South Africa, this is of great concern. Objectives: To determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa. Methods: We conducted a retrospective study of 350 ART-naïve adult patients attending the King Edward VIII HIV clinic, Durban, South Africa. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Renal function was assessed in the 24-month period using the Modification of Diet in Renal Disease equation and was categorised into normal renal function (estimated glomerular filtration rate [eGFR] ≥ 60), moderate renal impairment (eGFR 30–59), severe renal impairment (eGFR 15–29) and kidney failure (eGFR < 15 mL/min/1.73 m2). Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline. Results: The cohort was 64% female, and 99% were Black. The median age was 36 years. At baseline, 10 patients had hypertension (HPT), six had diabetes, 61 were co-infected with tuberculosis (TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorised as overweight and 19.4% as obese. The majority of the patients (59.3%) were normotensive. At baseline, the majority of the patients (90.4%) had normal renal function (95% CI: 86% – 93%), 7.0% (CI: 5% – 10%) had moderate renal impairment, 1.3% (CI: 0% – 3%) had severe renal impairment and 1.3% (CI: 0% – 3%) had renal failure. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03–1.10) times. The association of HPT with abnormal renal function was found to be insignificant, p > 0.05. The vast majority of patients were initiated on tenofovir disoproxil fumarate (TDF) (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%). Conclusion: This study reports a low prevalence of baseline renal impairment in HIV-infected ART-naïve outpatients. An improvement in renal function after the commencement of ART has been demonstrated in this population. However, the long-term outcomes of patients with HIV-related renal disease are not known.
- 19 January 2018
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 19 (1) , 11
Open AccessRisk factors and co-morbidities associated with changes in renal function among antiretroviral treatment-naïve adults in South Africa: A chart review
Introduction: Our systematic scoping review has demonstrated a research gap in antiretroviral treatment (ART) nephrotoxicity as well as in the long-term outcomes of renal function for patients on ART in South Africa. Bearing in mind the high prevalence of human immunodeficiency virus (HIV) in South Africa, this is of great concern. Objectives: To determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa. Methods: We conducted a retrospective study of 350 ART-naïve adult patients attending the King Edward VIII HIV clinic, Durban, South Africa. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Renal function was assessed in the 24-month period using the Modification of Diet in Renal Disease equation and was categorised into normal renal function (estimated glomerular filtration rate [eGFR] ≥ 60), moderate renal impairment (eGFR 30–59), severe renal impairment (eGFR 15–29) and kidney failure (eGFR < 15 mL/min/1.73 m2). Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline. Results: The cohort was 64% female, and 99% were Black. The median age was 36 years. At baseline, 10 patients had hypertension (HPT), six had diabetes, 61 were co-infected with tuberculosis (TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorised as overweight and 19.4% as obese. The majority of the patients (59.3%) were normotensive. At baseline, the majority of the patients (90.4%) had normal renal function (95% CI: 86% – 93%), 7.0% (CI: 5% – 10%) had moderate renal impairment, 1.3% (CI: 0% – 3%) had severe renal impairment and 1.3% (CI: 0% – 3%) had renal failure. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03–1.10) times. The association of HPT with abnormal renal function was found to be insignificant, p > 0.05. The vast majority of patients were initiated on tenofovir disoproxil fumarate (TDF) (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%). Conclusion: This study reports a low prevalence of baseline renal impairment in HIV-infected ART-naïve outpatients. An improvement in renal function after the commencement of ART has been demonstrated in this population. However, the long-term outcomes of patients with HIV-related renal disease are not known.